2024 Mar 1;22(1):225
Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials
It is believed to be mainly active in adults in contrast to IGF-2, which is also a major fetal growth factor
Fiji Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market (2026-2032) | Value, Trends, Forecast, Companies, Segmentation, Analysis, Size & Revenue, Share, Competitive Landscape, Industry, Growth, Outlook Market Forecast By GLP-1 Receptor Agonists (Exenatide, Liraglutide (Victoza), Lixisenatide (Lyxumia), Dulaglutide (Trulicity), Semaglutide (Ozempic)), By Insulin Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, Biosimilar Insulins) And Competitive Landscape Fiji Insulin Drugs and Glucagon-like Peptide 1 (Glp-1) Receptor Agonist Market Top 5 Importing Countries and Market Competition (HHI) Analysis In 2024, Fiji continued to heavily rely on imports of insulin drugs and GLP-1 receptor agonists, with the top exporting countries being Australia, New Zealand, India, Bangladesh, and the USA
Michela Starace was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions
